The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

The good news, I guess, is that we have very many different treatment options for relapse refractory multiple myeloma, and some of that is considered in the background of what we do for patients with ...

Creative Biolabs has a professional platform that provides customized CAR construction and design, meeting diverse needs of CAR-T cell therapy resear ...

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine discusses key takeaways from the ...

Multiple myeloma bone lesions occur when cancerous cells cause the bones to form weak spots, which can lead to breaks. Learn more about lesions and pain.

During early drug development and preclinical development, researchers use in vitro cultured lymphocytes to induce cytokine ...